다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Annals of rehabilitation medicine, v.36 no.2, 2012년, pp.207 - 212
Kim, Hyung Kuk (Department of Rehabilitation Medicine, Hanyang University College of Medicine, Seoul 133-792, Korea.) , Park, Si-Bog (Department of Rehabilitation Medicine, Hanyang University College of Medicine, Seoul 133-792, Korea.) , Park, Jong Woo (Department of Rehabilitation Medicine, Hanyang University College of Medicine, Seoul 133-792, Korea.) , Jang, Seong-Ho (Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri 471-701, Korea.) , Kim, Tae-Hwan (Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul 133-792, Korea.) , Sung, Yoon-Kyoung (Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul 133-792, Korea.) , Jun, Jae-Bum (Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul 133-792, Korea.)
AI-Helper
ObjectiveTo evaluate the prevalence and risk factors of peripheral neuropathy in patients with rheumatoid arthritis (RA) treated with leflunomide (LEF) by quantitative sensory testing (QST).MethodA total of 94 patients were enrolledin this study, out of which 47 patients received LEF. The other 47 p...
1 Breedveld FC Dayer JM Leflunomide: mode of action in the treatment of rheumatoid arthritis Ann Rheum Dis 2000 59 841 849 11053058
2 Elkayam O Yaron I Shirazi I Judovitch R Caspi D Yaron M Active leflunomide metabolite inhibits interleukin 1beta, tumor necrosis factor alpha, nitric oxide and metalloproteinase-3 production in activated human synovial tissue cultures Ann Rheum Dis 2003 62 440 443 12695157
3 Palmer G Burger D Mezein F Magne D Gabay C Dayer JM Guerne PA The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes Arthritis Res Ther 2004 6 R181 R189 15142263
4 Saag KG Teng GG Patkar NM Anuntiyo J Finney C Curtis JR Paulus HE Mudano A Pisu M Elkins-Melton M American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis Arthritis Rheum 2008 59 762 784 18512708
5 Kremer JM Cannon GW Benefit/risk of leflunomide in rheumatoid arthritis Clin Exp Rheumatol 2004 22 5 suppl 35 S95 S100 15552521
6 van Riel PL Smolen JS Emery P Kalden JR Dougados M Strand CV Breedveld FC Leflunomide: a manageable safety profile J Rheumatol Suppl 2004 71 21 24 15170904
7 van Roon EN Jansen TL Houtman NM Spoelstra P Brouwers JR Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity Drug Saf 2004 27 345 352 15061688
8 Rozman B Praprotnik S Logar D Tomsic M Hojnik M Kos-Golja M Accetto R Dolenc P Leflunomide and hypertension Ann Rheum Dis 2002 61 567 569 12006342
9 Ito S Sumida T Interstitial lung disease associated with leflunomide Intern Med 2004 43 1103 1104 15645640
10 Metzler C Arlt AC Gross WL Brandt J Peripheral neuropathy in patients with systemic rheumatic diseases treated with leflunomide Ann Rheum Dis 2005 64 1798 1800 16284351
11 Martin K Bentaberry F Dumoulin C Longy-Boursier M Lifermann F Haramburu F Dehais J Schaeverbeke T Begaud B Moore N Neuropathy associated with leflunomide: a case series Ann Rheum Dis 2005 64 649 650 15769926
12 Kho LK Kermode AG Leflunomide-induced peripheral neuropathy J Clin Neurosci 2007 14 179 181 17107800
13 Richards BL Spies J McGill N Richards GW Vaile J Bleasel JF Youssef PP Effect of leflunomide on the peripheral nerves in rheumatoid arthritis Intern Med J 2007 37 101 107 17229252
14 American Diabetes Association American Academy of Neurology Consensus statement: Report and recommendations of the San Antonio Conference of Diabetic Neuropathy Diabetes Care 1988 11 592 597 3060328
15 Dyck PJ Bushek W Spring EM Karnes JL Litchy WJ O'Brien PC Service FJ Vibratory and cooling detection threshold compared with other tests in diagnosing and staging diabetic neuropathy Diabetes Care 1987 10 432 444 3622200
16 Arnett FC Edworthy SM Bloch DA McShane DJ Fries JF Cooper NS Healey LA Kaplan SR Liang MH Luthra HS The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 1988 31 315 324 3358796
17 Bonnel RA Graham DJ Peripheral neuropathy in patients treated with leflunomide Clin Pharmacol Ther 2004 75 580 585 15179412
18 Lee SM Kim BJ Diagnostic usefulness of quantitative sensory test in diabetic polyneuropathy: comparison with nerve conduction study J Korean Neurol Assoc 1999 17 106 111
19 Carulli MT Davies UM Peripheral neuropathy: an unwanted effect of leflunomide? Rheumatology 2002 41 952 953 12154221
20 Kim HC Jun JB Lee KA Kim D Kim HS Kim SH A case of peripheral neuropathy in a patient with rheumatoid arthritis treated with leflunomide J Korean Rheum Assoc 2008 15 273 276
21 Martin K Bentaberry F Dumoulin C Miremont-Salame G Haramburu F Dehais J Schaeverbeke T Peripheral neuropathy associated with leflunomide: is there a risk patient profile? Pharmacoepidemiol Drug Saf 2007 16 74 78 16845649
22 Fox RI Herrmann ML Frangou CG Wahl GM Morris RE Strand V Kirschbaum BJ Mechanism of action for leflunomide in rheumatoid arthritis Clin Immunol 1999 93 198 208 10600330
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.